Intensive consolidation chemotherapy for newly diagnosed acute myeloid leukemia using a regime containing moderate dose cytosine arabinoside and mitoxantrone

Liang, Raymond; Chan, TK; Yc, Chu; Chan, John K. C.; Chen, Chan; Chiu, Ekw; A, Lie; Kwong, Yok–Lam; Ym, Yeung; Chan, Leo Lai

doi:10.1097/00001813-199504000-00005

Anti-Cancer Drugs

1995

DOI: 10.1097/00001813-199504000-00005

|View full text |Cite

Intensive consolidation chemotherapy for newly diagnosed acute myeloid leukemia using a regime containing moderate dose cytosine arabinoside and mitoxantrone

Raymond Liang

TK Chan²,

Chu Yc³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1997

1999

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Mitoxantrone in the treatment of acute myelogenous leukemia: a review

Thomas

Archimbaud

1997

Hematol Cell Ther

View full text Add to dashboard Cite

Mitoxantrone is an intravenous anthracenedione structurally related to the anthracycline antibiotics. This drug has been used for several years in the treatment of acute myelogenous leukemia (AML). Its use has been based on its pharmacological properties, its incomplete cross-resistance with other intercalating agents, and its better tolerance as predicted by preclinical studies. Various treatment schedules, using mitoxantrone alone and in combination with other antileukemic agents, have been used in clinical trials. Complete remission (CR) rates ranged from 14 to 44% in refractory AML and from 46 to 79% in relapsed patients. Although a superiority of mitoxantrone over anthracyclines has not been clearly demonstrated in newly diagnosed patients, mitoxantrone is now recognized as a useful drug in first line therapy. The tolerability profile of mitoxantrone indicates that it offers patients an acceptable quality of life compared with standard treatment regimens, and could be a good alternative to the anthracyclines. The development of new therapeutic concepts aiming at an optimization of its use is now in process and first results are promising.

show abstract

Mitoxantrone in the treatment of acute myelogenous leukemia: a review

Thomas

Archimbaud

1997

Hematol Cell Ther

View full text Add to dashboard Cite

show abstract

Treatment of de novo acute myeloid leukaemia in Hong Kong: a twenty‐year experience (1975 to 1996)

Chim

Liang

Kwong

et al. 1999

Australian and New Zealand Journal of Medicine

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Intensive consolidation chemotherapy for newly diagnosed acute myeloid leukemia using a regime containing moderate dose cytosine arabinoside and mitoxantrone

Cited by 2 publications

References 0 publications

Mitoxantrone in the treatment of acute myelogenous leukemia: a review

Mitoxantrone in the treatment of acute myelogenous leukemia: a review

Treatment of de novo acute myeloid leukaemia in Hong Kong: a twenty‐year experience (1975 to 1996)

Contact Info

Product

Resources

About